No connection

Search Results

Corporate Score 25 Neutral

Nuvation Bio CRO Kerry Wentworth Liquidates 200,000 Shares

Apr 13, 2026 04:24 UTC
NUVB
Short term

Chief Regulatory Officer Kerry Wentworth sold a significant portion of his direct holdings following the exercise of stock options. The transaction is characterized as a routine liquidity event rather than a reflection of company fundamentals.

  • Sale of 200,000 Class A shares at $4.52 per share
  • Total transaction value of approximately $904,000
  • Direct ownership reduced from 253,000 to 53,000 shares
  • Executive retains 700,000 stock options
  • Nuvation Bio reported a full-year net loss of $204.6 million

Kerry Wentworth, the Chief Regulatory Officer of Nuvation Bio (NYSE: NUVB), has sold 200,000 shares of Class A Common Stock. According to an SEC Form 4 filing, the transaction took place on April 6, 2026, at a weighted average price of $4.52 per share, totaling approximately $904,000. The sale followed the exercise of stock options, a common practice for executives to realize gains from their compensation packages. This transaction reduced Wentworth's direct Class A holdings from 253,000 to 53,000 shares, representing a 79% reduction in his direct ownership. Nuvation Bio continues to operate as a clinical-stage biopharmaceutical firm focused on oncology therapeutics. While the company reported a full-year net loss of roughly $204.6 million, such figures are typical for biotech firms heavily invested in research and development. The company's pipeline includes the oncology medication Ibtrozi. Despite the size of the sale, Wentworth retains 53,000 shares and holds 700,000 options that can be converted to common stock. Market analysts generally view the move as a personal financial decision rather than a bearish signal regarding the company's future performance or pipeline success.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Share this article

Related Articles

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Home
Terminal
AI
Markets
Profile